Any current/future new fundraising through debt or equity?

The company has not indicated any current plans for new fundraising through debt or equity. It reported a significant reduction in gross debt from Rs.548 crore (March 2023) to Rs.427 crore (September 2023) and net debt down to Rs.18 crore. The company is generating strong cash flows (around Rs.500 crore annually). Management separates debt and M&A plans, indicating no long-term debt concerns. There is no mention of immediate equity fundraising. CAPEX plans for the year are funded from internal resources, including Rs.145 crore planned for facility expansion. Overall, the focus appears to be on

Any current/future capex/capital investment/strategic investment?

Current FY24 CAPEX guidance is Rs.145 crore, including: - Rs.50 crore for land acquisition adjacent to the current lozenges manufacturing unit (futuristic expansion). - Around Rs.70 crore is maintenance CAPEX. - Marginal expansion of granulation tablet unit. Land acquisition is in preparation for doubling manufacturing capacity over 2-3 years. No immediate plans to add new medical reps, focusing on productivity growth. Exploring expansion in international geographies like the Philippines, but no near-term costs or launches expected (1-2 years away). CDMO business is growing, aiming to do

Future growth expectations in sales/revenue/volumes?

Domestic India business is expected to grow at 12% to 14% annually, outpacing the market growth of 8%-12%. Chronic portfolio in India is growing strongly at 18%, compared to 10% market growth, and is a key growth driver. Acute portfolio growth is modest at around 6%-7%, with better traction expected in upcoming quarters. International business, excluding South Africa, grew mid-teens; overall international business expected to grow at healthy double digits (~12%) next year after South Africa base reset. CDMO business aims to reach close to $100 million revenue in about three years, supported by

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects continued healthy EBITDA margins, targeting the upper side of guidance between 25% to 27%, with ambitions to reach mid-teens growth. Domestic India business growth is forecasted at 12% to 14% for the full year, outperforming the Indian pharma market growth of 8% to 12%. Chronic segment growth remains strong at 18% year-on-year, outpacing the market’s 10%; the acute segment growth was about 6% in Q2. CDMO business aims to grow to $100 million in revenue within the next 3 years, doubling from current levels. Margin expansion potential exists beyond current 27.6%, with

J B Chemicals & Pharmaceuticals LtdQ2 FY24Pharmaceuticals & Biotechnology

J B Chemicals & Pharmaceuticals Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,409P/E: 53.8Market Cap: ₹38.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Domestic India business is expected to grow at 12% to 14% annually, outpacing the market growth of 8%-12%.
Chronic portfolio in India is growing strongly at 18%, compared to 10% market growth, and is a key growth driver.
Acute portfolio growth is modest at around 6%-7%, with better traction expected in upcoming quarters.
International business, excluding South Africa, grew mid-teens; overall international business expected to grow at healthy double digits (~12%) next year after South Africa base reset.
CDMO business aims to reach close to $100 million revenue in about three years, supported by new product launches and portfolio diversification.
Volume growth in India is approximately 5%-6%, balanced evenly with pricing growth.
New launches, especially in CDMO, expected in the second half of next year, supporting future growth.
The company targets increasing contribution from India and CDMO to 75%-80% of overall sales in mid to long term.

Margin guidance

Category 3

The company expects continued healthy EBITDA margins, targeting the upper side of guidance between 25% to 27%, with ambitions to reach mid-teens growth.
Domestic India business growth is forecasted at 12% to 14% for the full year, outperforming the Indian pharma market growth of 8% to 12%.
Chronic segment growth remains strong at 18% year-on-year, outpacing the market’s 10%; the acute segment growth was about 6% in Q2.
CDMO business aims to grow to $100 million in revenue within the next 3 years, doubling from current levels.
Margin expansion potential exists beyond current 27.6%, with margin improvements driven by higher chronic mix, rationalization of low-margin business, and CDMO contributions.
No immediate plans to add field force; focus is on enhancing productivity and organic growth plus selective bolt-on acquisitions for synergy and growth.

See what J B Chemicals & Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company has not indicated any current plans for new fundraising through debt or equity.
It reported a significant reduction in gross debt from Rs.548 crore (March 2023) to Rs.427 crore (September 2023) and net debt down to Rs.18 crore.
The company is generating strong cash flows (around Rs.500 crore annually).
Management separates debt and M&A plans, indicating no long-term debt concerns.
There is no mention of immediate equity fundraising.
CAPEX plans for the year are funded from internal resources, including Rs.145 crore planned for facility expansion.
Overall, the focus appears to be on organic growth, selective inorganic acquisitions funded via internal accruals, and maintaining a strong balance sheet rather than raising new external capital.

Order book

The transcript provided on page 15 and surrounding pages does not specifically mention details about the current or expected order book or pending orders for J.B. Chemicals & Pharmaceuticals Limited. The discussion focuses more on business segments, growth, margins, acquisitions, geographic expansion, and product pipeline. Key points related to business outlook but not specific order book details: - India and CDMO businesses expected to contribute close to 75%-80% of overall sales in the mid to long term. - CDMO business aiming to reach $100 million revenue in around 3 years. - India business growing at 12%-14%, with chronic therapies and acquired portfolios driving growth. - No specific quantitative disclosure on current or expected order backlog or pending orders. Therefore, no explicit data on order book or pending orders is available in the provided transcript.

See what J B Chemicals & Pharmaceuticals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Current FY24 CAPEX guidance is Rs.145 crore, including:
- Rs.50 crore for land acquisition adjacent to the current lozenges manufacturing unit (futuristic expansion).
- Around Rs.70 crore is maintenance CAPEX.
- Marginal expansion of granulation tablet unit.
Land acquisition is in preparation for doubling manufacturing capacity over 2-3 years.
No immediate plans to add new medical reps, focusing on productivity growth.
Exploring expansion in international geographies like the Philippines, but no near-term costs or launches expected (1-2 years away).
CDMO business is growing, aiming to double revenue to $100 million in mid to long term via portfolio expansion, new geographies, cost savings, and new product launches.
Company remains open to inorganic growth via bolt-on acquisitions aligned with strategic focus, maintaining a payback period target of under 6 years.

Track J B Chemicals & Pharmaceuticals Ltd — get its next earnings analysis in your feed

How does J B Chemicals & Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisJ B Chemicals & Pharmaceuticals Ltd

Rev 3Mar 3

See where J B Chemicals & Pharmaceuticals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does J B Chemicals & Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Compare J B Chemicals & Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What J B Chemicals & Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

J B Chemicals & Pharmaceuticals Ltd Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does J B Chemicals & Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What J B Chemicals & Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season